Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Externally Sponsored Research (ESR) (including investigator sponsored trials and collaborative research) will lead the strategy, oversight, and execution of Revolution Medicines' ESR processes within one of our disease areas. This role will ensure scientific rigor, compliance, and alignment of the ESR program with company and external regulatory guidelines. The individual will collaborate closely with internal and external stakeholders to drive excellence in external research. Specifically, this individual will partner with Medical Strategy, Clinical Operations, and others on strategic development and execution of the program. The opportunity involves leadership of ESR-specific scientific committees and broad visibility within the organization. The Director, ESR, reports to the head of the ESR program.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
Ph.D. or professional degree